These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
625 related articles for article (PubMed ID: 28031235)
21. Histone deacetylase inhibitors repress chondrosarcoma cell proliferation. Zhu J; Gu J; Ma J; Xu Z; Tao H J BUON; 2015; 20(1):269-74. PubMed ID: 25778327 [TBL] [Abstract][Full Text] [Related]
22. Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells. Dejligbjerg M; Grauslund M; Litman T; Collins L; Qian X; Jeffers M; Lichenstein H; Jensen PB; Sehested M Mol Cancer; 2008 Sep; 7():70. PubMed ID: 18789133 [TBL] [Abstract][Full Text] [Related]
23. Trichostatin A induces a unique set of microRNAs including miR-129-5p that blocks cyclin-dependent kinase 6 expression and proliferation in H9c2 cardiac myocytes. Majumdar G; Raghow R Mol Cell Biochem; 2016 Apr; 415(1-2):39-49. PubMed ID: 26946427 [TBL] [Abstract][Full Text] [Related]
24. Histone Deacetylase Inhibitor Trichostatin A Suppresses Cell Proliferation and Induces Apoptosis by Regulating the PI3K/AKT Signalling Pathway in Gastric Cancer Cells. An X; Wei Z; Ran B; Tian H; Gu H; Liu Y; Cui H; Zhu S Anticancer Agents Med Chem; 2020; 20(17):2114-2124. PubMed ID: 32593284 [TBL] [Abstract][Full Text] [Related]
25. (-)-Epigallocatechin-3-gallate reverses the expression of various tumor-suppressor genes by inhibiting DNA methyltransferases and histone deacetylases in human cervical cancer cells. Khan MA; Hussain A; Sundaram MK; Alalami U; Gunasekera D; Ramesh L; Hamza A; Quraishi U Oncol Rep; 2015 Apr; 33(4):1976-84. PubMed ID: 25682960 [TBL] [Abstract][Full Text] [Related]
26. TACC3 overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors. He JC; Yao W; Wang JM; Schemmer P; Yang Y; Liu Y; Qian YW; Qi WP; Zhang J; Shen Q; Yang T Oncotarget; 2016 Nov; 7(46):75441-75456. PubMed ID: 27705912 [TBL] [Abstract][Full Text] [Related]
27. Histone deacetylase inhibitor-induced cell death in bladder cancer is associated with chromatin modification and modifying protein expression: A proteomic approach. Li QQ; Hao JJ; Zhang Z; Hsu I; Liu Y; Tao Z; Lewi K; Metwalli AR; Agarwal PK Int J Oncol; 2016 Jun; 48(6):2591-607. PubMed ID: 27082124 [TBL] [Abstract][Full Text] [Related]
28. Histone deacetylases inhibitor trichostatin A increases the expression of Dleu2/miR-15a/16-1 via HDAC3 in non-small cell lung cancer. Chen CQ; Chen CS; Chen JJ; Zhou LP; Xu HL; Jin WW; Wu JB; Gao SM Mol Cell Biochem; 2013 Nov; 383(1-2):137-48. PubMed ID: 23867991 [TBL] [Abstract][Full Text] [Related]
29. Troglitazone inhibits histone deacetylase activity in breast cancer cells. Davies GF; Ross AR; Arnason TG; Juurlink BH; Harkness TA Cancer Lett; 2010 Feb; 288(2):236-50. PubMed ID: 19699029 [TBL] [Abstract][Full Text] [Related]
30. Effects of histone deacetylase inhibitors on regenerative cell responses in human dental pulp cells. Luo Z; Wang Z; He X; Liu N; Liu B; Sun L; Wang J; Ma F; Duncan H; He W; Cooper P Int Endod J; 2018 Jul; 51(7):767-778. PubMed ID: 28375564 [TBL] [Abstract][Full Text] [Related]
31. High dose of histone deacetylase inhibitors affects insulin secretory mechanism of pancreatic beta cell line. Yamato E Endocr Regul; 2018 Jan; 52(1):21-26. PubMed ID: 29453918 [TBL] [Abstract][Full Text] [Related]
32. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers. Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197 [TBL] [Abstract][Full Text] [Related]
33. Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors. Guan P; Sun F; Hou X; Wang F; Yi F; Xu W; Fang H Bioorg Med Chem; 2012 Jun; 20(12):3865-72. PubMed ID: 22579621 [TBL] [Abstract][Full Text] [Related]
34. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Munshi A; Kurland JF; Nishikawa T; Tanaka T; Hobbs ML; Tucker SL; Ismail S; Stevens C; Meyn RE Clin Cancer Res; 2005 Jul; 11(13):4912-22. PubMed ID: 16000590 [TBL] [Abstract][Full Text] [Related]
35. Transcriptome screening and verification of genes related to metabolism affected by histone deacetylase inhibitors. Cao JH; Liao WT; Wo C; Xu GR; Xu HX; Li P; Tao Y; Wang P; Lin JR; Deng LR Yi Chuan; 2015 Sep; 37(9):918-25. PubMed ID: 26399531 [TBL] [Abstract][Full Text] [Related]
36. Effect of Zebularine in Comparison to and in Combination with Trichostatin A on CIP/KIP Family (p21Cip1/Waf1/Sdi1, p27Kip1, and p57Kip2), DNMTs (DNMT1, DNMT3a, and DNMT3b), Class I HDACs (HDACs 1, 2, 3) and Class II HDACs (HDACs 4, 5, 6) Gene Expression, Cell Growth Inhibition and Apoptosis Induction in Colon Cancer LS 174T Cell Line. Sanaei M; Kavoosi F Asian Pac J Cancer Prev; 2020 Jul; 21(7):2131-2139. PubMed ID: 32711442 [TBL] [Abstract][Full Text] [Related]
37. Histone deacetylase inhibitors induced differentiation and accelerated mineralization of pulp-derived cells. Duncan HF; Smith AJ; Fleming GJ; Cooper PR J Endod; 2012 Mar; 38(3):339-45. PubMed ID: 22341071 [TBL] [Abstract][Full Text] [Related]
38. MiR-129-5p is required for histone deacetylase inhibitor-induced cell death in thyroid cancer cells. Brest P; Lassalle S; Hofman V; Bordone O; Gavric Tanga V; Bonnetaud C; Moreilhon C; Rios G; Santini J; Barbry P; Svanborg C; Mograbi B; Mari B; Hofman P Endocr Relat Cancer; 2011 Dec; 18(6):711-9. PubMed ID: 21946411 [TBL] [Abstract][Full Text] [Related]
39. Trichostatin A induces mesenchymal-like morphological change and gene expression but inhibits migration and colony formation in human cancer cells. Han RF; Li K; Yang ZS; Chen ZG; Yang WC Mol Med Rep; 2014 Dec; 10(6):3211-6. PubMed ID: 25269990 [TBL] [Abstract][Full Text] [Related]
40. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Kim YB; Lee KH; Sugita K; Yoshida M; Horinouchi S Oncogene; 1999 Apr; 18(15):2461-70. PubMed ID: 10229197 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]